A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer

TS-1, a novel oral formation of 5-fluorouracil, consists of tegafur (5-FU), CDHP and Oxo. Low-dose cisplatin (CDDP) and TS-1 was evaluated in 12 patients with advanced or recurrent gastric cancer. CDDP was given biweekly at a dose of 15 mg/m2 infused for 30 minutes, and 80 mg/body of TS-1 was orally...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 28; no. 10; p. 1419
Main Authors Kamata, T, Hayashi, Y, Minatoya, G, Michiwa, Y, Onishi, I, Takeda, T, Koyasaki, N, Kanno, M
Format Journal Article
LanguageJapanese
Published Japan 01.10.2001
Subjects
Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Cisplatin - administration & dosage
Drug Administration Schedule
Drug Combinations
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Oxonic Acid - administration & dosage
Pilot Projects
Pyridines - administration & dosage
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Survival Rate
Tegafur - administration & dosage
Online AccessGet more information

Cover

More Information
Summary:TS-1, a novel oral formation of 5-fluorouracil, consists of tegafur (5-FU), CDHP and Oxo. Low-dose cisplatin (CDDP) and TS-1 was evaluated in 12 patients with advanced or recurrent gastric cancer. CDDP was given biweekly at a dose of 15 mg/m2 infused for 30 minutes, and 80 mg/body of TS-1 was orally administered as many times as possible. The response rate was 41.7%. Median survival time was 13.3 months. In one case, an adverse reaction of grade 3 leucopenia was observed. Thus, thought it is necessary to watch for leucopenia, this chemotherapy could well be effective for patients with advanced or recurrent gastric cancer.
ISSN:0385-0684